Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
November 21, 2023 01:00 ET
|
Pharming Group N.V.
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The...
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
November 10, 2023 08:51 ET
|
Pharming Group N.V.
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of...
Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting
November 07, 2023 02:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its...
Pharming Group to participate in November investor conferences
November 01, 2023 03:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports third quarter 2023 financial results
October 26, 2023 01:00 ET
|
Pharming Group N.V.
Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and...
Pharming Group to report third quarter 2023 financial results on October 26
October 12, 2023 02:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial...
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
September 25, 2023 10:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders...
Pharming Reports On Preliminary Financial Results 2013
March 06, 2014 01:13 ET
|
Pharming Group N.V.
LEIDEN, Netherlands, March 6, 2014 (GLOBE NEWSWIRE) --
Revenues and other income decreased to €7.0 million (2012: €10.9 million) mainly as a result from lower license fees as 2012...
PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)
February 24, 2014 01:12 ET
|
Pharming Group N.V.
LEIDEN, Netherlands and RALEIGH, N.C., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Pharming Group NV (NYSE Euronext:PHARM) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Food and Drug...
PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR)
November 08, 2013 01:06 ET
|
Pharming Group N.V.
LEIDEN, Netherlands and SAN DIEGO, Nov. 8, 2013 (GLOBE NEWSWIRE) --
Pharming Group NV (NYSE
Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) announced that new data from
an open-label extension of...